



HEALTHCARE

Pharmaceutical Pricing and Reimbursement

Strategies for market access across the US, Europe, Japan and other key geographies

By Steven Seget

 [Table of Contents](#)

Steven Seget

Steven Seget is Principal at Delphi Pharma, and provides independent strategic consulting services to the pharmaceutical and biotechnology industries. Steven previously managed the strategic healthcare consulting function at Datamonitor and has an MBA from the London Business School. sseget@delphipharma.com

Delphi Pharma provides strategic, financial and market-based solutions to clients, focusing primarily on the portfolio management, business development and licensing functions. Delphi Pharma combines an extensive research network, applied analytical expertise and an established track record to deliver high value results and measurable impact to its clients. www.delphipharma.com

Copyright © 2007 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Reuters. Reuters accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

REUTERS and dotted and sphere logos are the house trade marks of Reuters Limited in more than 25 countries world-wide.

Printed and bound in Great Britain by FPC Greenaway. Ormolu House, Crimscott Street, London SE1 5TE. www.greenaways.com

Table of Contents

Pharmaceutical Pricing and Reimbursement

Executive Summary	10	
An introduction to price optimization	10	
Pricing and reimbursement in North America	11	
Pricing and reimbursement in Europe	12	
Pricing and reimbursement in Japan and the rest of the world	13	
Global pricing strategies	14	
Lifecycle pricing strategies	15	
Chapter 1	An introduction to price optimization	18
Summary		18
Introduction		19
Delivering a return on investment		19
Sustained R&D productivity shortfall		19
Impending blockbuster patent expiries		23
Healthcare cost containment		24
Cost-containment initiatives		26
Pharmaceutical spend cost containment		27
Key issues impacting on pricing		29
Pharmaceutical price optimization		29
Pricing and reimbursement regulations		30
Reference pricing		34
Pharmacoeconomic evaluations		34
Parallel imports and reimportation		35
Generic substitution		37
Global versus lifecycle pricing		38

Italian pricing regulations	75
State of the industry	77
Recent developments in Italy	77
Regional cost-containment	77
2007 Finance Law	78
Spanish pricing regulations	78
State of the industry	80
Recent developments in Spain	81
Regional cost-containment	81
Modified reference price system	82
Anti-parallel trade strategies	82
UK pricing regulations	83
Recent developments in the UK	84
The future of the PPRS	84
Risk sharing schemes	85
Declining parallel trade	86
Expanding the NICE remit	86
Future pricing scenarios in Europe	87
Best case pricing scenario	87
Worst case pricing scenario	88
Most likely pricing scenario	89

Chapter 4 Pricing and reimbursement in Japan and the rest of the world 92

Summary	92
Introduction	93
Japanese pricing regulations	93
Recent developments in Japan	95
Biennial price cut	95
Generic substitution introduced	97
Future pricing scenarios in Japan	97
Best case pricing scenario	98
Worst case pricing scenario	99
Most likely pricing scenario	100
Australian pricing regulations	101
Benchmark pricing	102
Cost plus method	102
Average monthly treatment cost	103
Prices for new items	103
Recent developments in Australia	104
Pharmaceutical Benefits Scheme reform	104
Chinese pricing regulations	104

Recent developments in China	105
New drug pricing procedures	105
Price cuts	106
Generic prescribing	106
Chapter 5	Global pricing strategies
	108
Summary	108
Introduction	109
Local optimization	109
Market access and reimbursement	109
Free price markets	110
Orphan drugs	111
Pharmacoeconomic evaluations	111
Global coordination	113
Launch sequence	113
EU launch order	114
Optimal price differentials	115
Implementing global pricing strategies	119
Chapter 6	Lifecycle pricing strategies
	122
Summary	122
Introduction	123
Launch phase pricing considerations	123
Submission dossiers	123
Identifying key decision makers	125
Failure to secure reimbursement	126
Working with decision makers	126
Applying pressure through lobbying	127
Brokering deals	127
Patent protected phase pricing considerations	128
Case study: the respiratory market	128
Innovative pricing strategies	131
Patent expiry phase pricing considerations	132
Price changes	132
US patent expiry	133
European patent expiry	134
Case study: generic simvastatin	135
Biosimilar pricing	136
Implementing lifecycle pricing strategies	137

Chapter 7

Appendix

140

Glossary

140

Sources

142

List of Figures

Figure 1.1:	Declining trend in number of NDA and NME approvals, 1997-2006	21
Figure 1.2:	Rise in the cost of drug development, 1975-2001	23
Figure 1.3:	US patent expiries for top ten selling drugs, 2006-2011	24
Figure 1.4:	Trends in healthcare spending as a proportion of GDP, 1970-2005	26
Figure 1.5:	Pharmaceutical expenditure as a share of total healthcare expenditure in 2005	27
Figure 2.6:	Source of prescription drug expenditures, 2005-2006	53
Figure 2.7:	Canadian cross border internet pharmacy sales, 2002-2006	55
Figure 2.8:	Compensatory final settlements (reverse payments), 2004-2006	57
Figure 3.9:	Average ex-factory drug prices in key European markets, 2005	81
Figure 4.10:	NHI price cuts by therapeutic class, 2006	96
Figure 5.11:	Market share for new products launched in last five years, 2005	110
Figure 5.12:	External reference pricing in Europe, 2007	117
Figure 5.13:	Global pricing and the interaction between countries	118
Figure 5.14:	Global pricing strategies	120
Figure 6.15:	Leading respiratory drugs by global sales, 2006	129
Figure 6.16:	Lifecycle pricing strategies	138

List of Tables

Table 1.1:	Number of NDA and NME approvals by the FDA, 1990-2006	20
Table 1.2:	R&D expenditure within the US and abroad by PhRMA members, 1980-2006	22
Table 1.3:	Trends in healthcare spending as a proportion of GDP, 1970-2005 (%)	25
Table 2.4:	Future pricing scenarios in the US	58
Table 3.5:	Future pricing scenarios in Europe	87
Table 4.6:	Co-payments for drugs/services in Japan	94
Table 4.7:	Classification for price premium (Japanese healthcare system)	95
Table 4.8:	Future pricing scenarios in Japan	98